ABSTRACT
Bone disease in rheumatoid arthritis (RA) is a complex phenomenon where genetic risk factors have been partially evaluated. The system formed by receptor activator for nuclear factor-κB (RANK), receptor activator for nuclear factor-κB ligand (RANKL), and osteoprotegerin (OPG): RANK/RANKL/OPG is a crucial molecular pathway for coupling between osteoblasts and osteoclasts, since OPG is able to inhibit osteoclast differentiation and activation. We aim to evaluate the association between SNPs C950T (rs2073617), C209T (rs3134069), T245G (rs3134070) in the TNFRSF11B (OPG) gene, and osteoporosis in RA. We included 81 women with RA and 52 healthy subjects in a cross-sectional study, genotyped them, and measured bone mineral density (BMD) at the lumbar spine and the femoral neck. Mean age in RA was 50 ± 12 with disease duration of 12 ± 8 years. According to BMD results, 23 (33.3%) were normal and 46 (66.7%) had osteopenia/osteoporosis. We found a higher prevalence of C allele for C950T SNP in RA. Polymorphisms C209T and T245G did not reach statistical significance in allele distribution. Further studies including patients from other regions of Latin America with a multicenter design to increase the sample size are required to confirm our findings and elucidate if C950T SNP could be associated with osteoporosis in RA.
Subject(s)
Arthritis, Rheumatoid/genetics , Osteoporosis/genetics , Osteoprotegerin/genetics , Polymorphism, Single Nucleotide/genetics , Adult , Aged , Alleles , Bone Density/genetics , Case-Control Studies , Cross-Sectional Studies , Female , Genotype , Humans , Mexico , Middle Aged , RANK Ligand/genetics , Receptor Activator of Nuclear Factor-kappa B/genetics , Risk Factors , Young AdultABSTRACT
Las vacunas terapéuticas en cáncer, constituyen una novedosa estrategia inmunoterapéutica y tienen como objetivo estimular o potenciar en el huésped una respuesta inmunitaria contra los antígenos del tumor. Esta forma de terapia basada en la manipulación del sistema inmune puede complementar los tratamientos oncológicos convencionales; en la actualidad existen diversas preparaciones vacunales que se encuentran en etapa de ensayos clínicos en diferentes localizaciones tumorales. Esta revisión tiene como objetivo ofrecer una actualizada panorámica sobre el fundamento, la clasificación y las aplicaciones más importantes de las principales vacunas que hoy se investigan en los tumores malignos(AU)
Subject(s)
Neoplasms/immunology , Neoplasms/therapy , Immunotherapy , Cancer Vaccines/therapeutic use , Antigens, Neoplasm , Clinical Trials as TopicABSTRACT
Multiple immune impairments in Non-Hodgkin patients are associated with their clinical development. The aim of this study was to describe the composition of peripheral T cell subpopulations before treatment in patients who died from infection or serious radiogenic complication together with tumoral activity. During a follow-up period of 8.18 years as an average; 5 cases affected by any of these complications which were not controlled by the treated were recorded. Lymphocytopenia CD3+ was the only common datum observed in the analysis covering variables of recognized prognostic death value. It was concluded that the low CD3+ count is a comorbid prognostic factor in Non-Hodgkin lymphoma that should not be ignored because of its fatal consequences
Subject(s)
Humans , Immunosuppression Therapy , Lymphopenia , Prognosis , T-Lymphocytes , Immune Tolerance/radiation effectsABSTRACT
Multiple immune impairments in Non-Hodgkin patients are associated with their clinical development. The aim of this study was to describe the composition of peripheral T cell subpopulations before treatment in patients who died from infection or serious radiogenic complication together with tumoral activity. During a follow-up period of 8.18 years as an average; 5 cases affected by any of these complications which were not controlled by the treated were recorded. Lymphocytopenia CD3+ was the only common datum observed in the analysis covering variables of recognized prognostic death value. It was concluded that the low CD3+ count is a comorbid prognostic factor in Non-Hodgkin lymphoma that should not be ignored because of its fatal consequences
